Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells (Q42771088)

7 November 2017

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells (English)

1 reference

7 November 2017

Marcia A Chan

1 reference

7 November 2017

Nicole M Gigliotti

series ordinal

1 reference

7 November 2017

Abby L Dotson

series ordinal

1 reference

7 November 2017

Lanny J Rosenwasser

series ordinal

1 reference

7 November 2017

2 September 2013

1 reference

Clinical and translational allergy

7 November 2017

1 reference

7 November 2017

1 reference

7 November 2017

1 reference

7 November 2017

1 reference

Soluble CD23 controls IgE synthesis and homeostasis in human B cells.

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

CD23-mediated cell signaling in human B cells differs from signaling in cells of the monocytic lineage

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

CD23: an overlooked regulator of allergic disease.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Molecular and cellular targets of anti-IgE antibodies

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The regulation of immunoglobulin E class-switch recombination

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The role of immunoglobulin E in allergy and asthma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The pharmacological basis of anti-IgE therapy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The IL-4 receptor: signaling mechanisms and biologic functions

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Regulation of interleukin-13 receptor constituents on mature human B lymphocytes

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Omalizumab is effective in the long-term control of severe allergic asthma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

The effect of omalizumab on nasal allergic inflammation

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Reduced life span of anergic self-reactive B cells in a double-transgenic model

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3875359

Requirement for dual signals by anti-CD40 and IL-4 for the induction of nuclear factor-kappa B, IL-6, and IgE in human B lymphocytes

16 August 2018

1 reference

12 December 2020

MIP-1alpha induces differential MAP kinase activation and IkappaB gene expression in human B lymphocytes

1 reference

12 December 2020

Predicting and evaluating response to omalizumab in patients with severe allergic asthma

1 reference

12 December 2020

A polyclonal model for B cell tolerance. I. Fc-dependent and Fc-independent induction of nonresponsiveness by pretreatment of normal splenic B cells with anti-Ig

1 reference

12 December 2020

Identifiers

DOI

10.1186/2045-7022-3-29

1 reference

Dimensions Publication ID

7 November 2017

1039147598

0 references

Fatcat ID

release_rwdqzcboxrahhn3cudtibuckcu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rwdqzcboxrahhn3cudtibuckcu

24 November 2022

mapped directly with Wikidata item

1 reference

7 November 2017

PubMed publication ID

24004581

1 reference